派林生物
(000403)
| 流通市值：148.24亿 | | | 总市值：158.28亿 |
| 流通股本：6.85亿 | | | 总股本：7.31亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,890,265,336.27 | 1,136,178,207.09 | 435,640,719.29 | 2,328,723,280.44 |
| 营业收入 | 1,890,265,336.27 | 1,136,178,207.09 | 435,640,719.29 | 2,328,723,280.44 |
| 二、营业总成本 | 1,279,639,389.94 | 772,121,600.72 | 297,485,500.88 | 1,639,495,501.1 |
| 营业成本 | 935,384,603.19 | 565,852,267.76 | 211,639,380.49 | 1,129,878,426.98 |
| 税金及附加 | 15,460,100.12 | 9,465,540.79 | 4,538,798.74 | 21,690,609.99 |
| 销售费用 | 188,685,182.04 | 102,990,377.6 | 33,956,526.07 | 285,567,024.07 |
| 管理费用 | 131,080,445.38 | 85,128,904.23 | 39,943,531.34 | 180,246,109.48 |
| 研发费用 | 45,975,375.17 | 33,639,295.65 | 20,864,588.5 | 79,685,080.96 |
| 财务费用 | -36,946,315.96 | -24,954,785.31 | -13,457,324.26 | -57,571,750.38 |
| 其中:利息费用 | 7,684,012.88 | 5,479,758.44 | 2,008,831.5 | 9,625,607.06 |
| 其中:利息收入 | 44,948,849.62 | 30,701,295.34 | 15,691,811.84 | 67,681,210.74 |
| 加:公允价值变动收益 | -10,592,156.39 | -13,703,192.18 | -4,238,555.62 | -18,969,711.52 |
| 加:投资收益 | 29,389,560.54 | 24,374,736.66 | 8,645,797.49 | 7,402,129.64 |
| 资产处置收益 | 58,070.35 | 683,961.62 | 595,399.82 | -544,960.49 |
| 信用减值损失(新) | 2,858,186.89 | 1,870,012.59 | 1,441,118.91 | 3,211,026.44 |
| 其他收益 | 6,412,568.03 | 5,214,726.47 | 4,515,024.5 | 14,861,369 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 638,752,175.75 | 382,496,851.53 | 149,114,003.51 | 695,187,632.41 |
| 加:营业外收入 | 105,896.52 | 98,675.6 | 107,879.55 | 3,531,734.98 |
| 减:营业外支出 | 19,311,603.61 | 11,742,761.68 | 8,272,232.99 | 10,610,544.79 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 619,546,468.66 | 370,852,765.45 | 140,949,650.07 | 688,108,822.6 |
| 减:所得税费用 | 76,788,008.59 | 43,876,961.28 | 19,079,874.51 | 76,636,351.61 |
| 六、净利润 | 542,758,460.07 | 326,975,804.17 | 121,869,775.56 | 611,472,470.99 |
| 持续经营净利润 | 542,758,460.07 | 326,975,804.17 | 121,869,775.56 | 611,472,470.99 |
| 归属于母公司股东的净利润 | 542,732,944.36 | 326,984,394.22 | 121,948,626.85 | 612,111,043.76 |
| 少数股东损益 | 25,515.71 | -8,590.05 | -78,851.29 | -638,572.77 |
| (一)基本每股收益 | 0.74 | 0.45 | 0.17 | 0.84 |
| (二)稀释每股收益 | 0.74 | 0.45 | 0.17 | 0.84 |
| 八、其他综合收益 | -5,639.91 | 3,460.4 | 1,014.2 | 11,039.38 |
| 归属于母公司股东的其他综合收益 | -5,639.91 | 3,460.4 | 1,014.2 | 11,039.38 |
| 九、综合收益总额 | 542,752,820.16 | 326,979,264.57 | 121,870,789.76 | 611,483,510.37 |
| 归属于母公司股东的综合收益总额 | 542,727,304.45 | 326,987,854.62 | 121,949,641.05 | 612,122,083.14 |
| 归属于少数股东的综合收益总额 | 25,515.71 | -8,590.05 | -78,851.29 | -638,572.77 |
| 公告日期 | 2024-10-28 | 2024-08-28 | 2024-04-27 | 2024-04-27 |
| 审计意见(境内) | | | | 标准无保留意见 |